Menkes Disease Market

DelveInsight’s ‘Menkes Disease-Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Menkes Disease, historical and forecasted epidemiology as well as the Menkes Disease market trends in the G11 i.e. United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, Australia, New Zealand, China, and South Korea.

 

The Menkes Disease market report provides current treatment practices, emerging drug, market share of the individual therapies, current and forecasted G11 Menkes Disease market size from 2019 to 2032. The Report also covers current Menkes Disease treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • Australia
  • New Zealand
  • China
  • South Korea

Study Period: 2019–2032

Menkes Disease Understanding and Treatment Algorithm

Menkes Disease Overview

Menkes disease (MD) is a lethal infantile neurodegenerative disorder with X-linked inheritance. It is an inherited X-linked recessive disorder caused by mutations in the ATP7A gene that is responsible for the transport of copper throughout the body. The mutation could lead to premature birth and may have non-specific symptoms such as hypothermia, hypoglycemia, and prolonged jaundice. These non-specific clinical and biochemical findings could result in the misdiagnosis of neonatal Menkes disease.

 

Menkes disease is usually inherited, which means it runs in families. The gene is on the X-chromosome, so if a mother carries the defective gene, each of her sons has a 50% (1 in 2) chance of developing the disease, and 50% of her daughters will be a carrier of the disease. The symptoms may not appear in infants until two to three months after birth.

 

Symptoms of Menkes disease begin shortly after birth and may vary from person to person. The typical symptoms usually start by two months with characteristic skin and hair findings. Sagging facial features, micrognathia, cutis laxa, and blue iris can be noted. Congenital malformations have been reported, including congenital microblepharia, entropion, long arched palate, cerebellar hypoplasia, cystic changes in the lungs, and complete AV block. Neurological manifestations are the most common and characteristic of Menkes disease. Developmental regression and seizures are usually the first to start around 2–3 months.

 

Occipital horn syndrome is a milder allelic variant of Menkes disease. ATP7A-related distal motor neuropathy is another identified allelic variant that involves a gradual, adult-onset distal motor neuropathy resembling Charcot–Marie–Tooth disease type 2.

 

Menkes Disease Diagnosis

Initial diagnosis is based on clinical features (typical hair changes associated with hypotonia and delayed neuromotor development) and supported by the demonstration of reduced levels of serum copper and ceruloplasmin.

 

Prenatal diagnosis can be possible where the pathogenic variant has a history in the family and it is a preferred test to determine the carrier status of the mother before pregnancy.

Continued in the report…..

 

Menkes Disease Treatment

Menkes disease is a fatal disease with death usually occurring between 6 months to 3 years. Menkes disease has no specific curative treatment, and it is a progressive multisystem disease. Treatment outcome depends on the severity of ATP7A gene deletion and residual functioning ATP7A protein.

 

The goal of the treatment is to provide copper to the copper-dependent enzymes.

 

It is crucial to begin treatment as early as possible. The current scenario allows treatment of neonatal Menkes patients with copper-histidine (before 30 days of life) for asymptomatic boys with a molecular or biochemical diagnosis. But in most cases, the disease does not get diagnosed in the early phase. However, early copper-histidine therapy does not normalize the neurological outcome in some patients. Such different responses to early treatment may be due to the different levels of residual Menkes disease ATPase activity in each patient or the formation of copper-histidine.

 

Treatment with copper-histidine after 30 days of life and for symptomatic boys with MD is not recommended.

 

It has been noted that copper administration is poorly absorbed when taken orally or intrarectally. For better outcomes, copper has been injected intravenously or subcutaneously in many different forms, such as copper-histidine, copper-acetate, and copper ethylenediaminetetraacetic acid (EDTA).

Continued in the report…..

Menkes Disease Epidemiology 

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of Menkes disease in the G11 covering the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, Australia, New Zealand, China, and South Korea from 2019 to 2032.

 

Key Findings

  • As per the assessment of DelveInsight, the total diagnosed prevalent cases of Menkes Disease in the G11 were found to be 265 in 2021, which are expected to increase at a Compound Annual Growth Rate (CAGR) of 6.12% during the study period.
  • Among G11, the United States had 79 diagnosed prevalent cases of Menkes Disease in 2021, which was equivalent to 30% of the total diagnosed prevalent cases in G11.
  • In 2021, the EU-5 accounted for 57 diagnosed prevalent cases of Menkes Disease, which will increase by 2032 at a CAGR of 5.97%.
  • Among the European countries, France had the highest diagnosed prevalent population of Menkes Disease with 15 cases, followed by Germany and UK with 14 cases in each country, in 2021. On the other hand, Spain had the lowest diagnosed prevalent population.
  • In 2021, Japan had 19 diagnosed cases of Menkes Disease. These cases are expected to increase by 2032 at a CAGR of 4.76% during the forecasted period (2022–2032).
  • In South Korea, 8 cases of Menkes Disease were estimated, in 2021.
  • China accounted highest diagnosed prevalent cases of Menkes Disease with 81 cases in 2021, in G11.

Country-Wise Menkes Disease Epidemiology

The epidemiology segment also provides the Menkes Disease epidemiology data and findings across the G11.

Menkes Disease Drug Chapters

The drug chapter segment of the Menkes Disease report encloses the detailed analysis of Menkes Disease mid- and late-stage pipeline drugs. It also helps to understand the Menkes Disease clinical trial details, expressive pharmacological action, agreements and collaborations, and patent details of each included drug and the latest news and press releases.

 

Menkes Disease Emerging Drugs

 

CUTX-101: Cyprium Therapeutics and Sentynl Therapeutics

Cyprium Therapeutics, in collaboration with Sentynl Therapeutics, is developing CUTX-101, a copper histidinate injection to treat Menkes disease. CUTX-101 has been granted Orphan Drug designation and Rare Pediatric Disease designation by the FDA for the treatment of Menkes disease, and Fast Track Designation for classic Menkes disease in patients who have not demonstrated significant clinical progression. The European Medicines Agency (EMA) Committee for Orphan Medicinal Products also granted Orphan Drug Designation for CUTX-101. In December 2020, the FDA granted Breakthrough Therapy Designation to CUTX-101. Along with multiple designation in the US and Europe, the drug is available for expanded access use, benefiting many patients. The Rolling NDA submission for the CUTX-101 to the FDA was initiated in December 2021, and submission is expected to complete in mid-2022. This drug will be the first ever to receive approval for Menkes disease.

Products detail in the report…

List to be continued in the report…

Menkes Disease Market Outlook

Disorders of copper homeostasis are currently recognized across the life span. Their recognition and links to human disease have spanned several decades, beginning with the recognition of a degenerative disorder in the offspring of sheep grazing in copper-deficient pastures, through to the description of infants suffering from a progressive neurodegenerative disorder characterized by epileptic seizures, developmental regression, failure to thrive, and an unusual hair quality (giving the condition its distinctive label of kinky hair disease)

 

The current scenario allows treatment of neonatal Menkes patients with copper-histidine (before 30 days of life) for asymptomatic boys with a molecular or biochemical diagnosis, while for patients diagnosed with the disease after 30 days of life is not suggested.

 

According to DelveInsight, the Menkes Disease treatment paradigm in the G11 is expected to change during the forecasted period 2022–2032.

 

Key Findings

  • The market size of Menkes Disease in the G11 market is expected to increase at a very high Compound Annual Growth Rate (CAGR) for the study period (2019–2032) from USD 0.2 million in 2021 to significant market size by 2032.
  • The expected launch of potential therapies may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of Menkes Disease.
  • Upcoming therapies such as CUTX-101 have the potential to create a significant positive shift in the Menkes Disease market size.
  • The United States accounts for the largest market size of Menkes Disease, in comparison to other countries of G11.
  • Among the EU-5 countries, Germany and France had the highest market size of Menkes Disease in 2021.

 

The United States Market Outlook

This section provides the total Menkes Disease market size and; market size by therapies in the United States.

 

EU-5 Market Outlook

The total Menkes Disease market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total Menkes Disease market size and market size by therapies in Japan are provided.

 

Australia Market Outlook

The total Menkes Disease market size and market size by therapies in Australia are provided.

 

New Zealand Market Outlook

The total Menkes Disease market size and market size by therapies in New Zealand are provided.

 

China Market Outlook

The total Menkes Disease market size and market size by therapies in China are provided.

 

South Korea Market Outlook

The total Menkes Disease market size and market size by therapies in South Korea are provided.

Menkes Disease Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Menkes Disease market or expected to get launched in the market during the study period 2019–2032. The analysis covers Menkes Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Menkes Disease Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stages. It also analyzes key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, merger, licensing, and patent details for Menkes Disease emerging therapies.

Reimbursement Scenario in Menkes Disease

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Menkes Disease market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Menkes Disease, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Menkes Disease epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Menkes Disease is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Menkes Disease market; historical and forecasted is included in the report, covering the G11 drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the G11 Menkes Disease market.

Report Highlights

  • The robust pipeline with novel MOA and oral ROA and increasing prevalence will positively drive the Menkes Disease market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Menkes Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Menkes Disease. The launch of emerging therapies will significantly impact the Menkes Disease market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Menkes Disease Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Menkes Disease Pipeline Analysis
  • Menkes Disease Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Menkes Disease Report Key Strengths

  • 11-Years Forecast
  • G11 Coverage

Menkes Disease Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Menkes Disease Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the Menkes Disease market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Menkes Disease total market size as well as market size by therapies across the G11 during the forecast period (2022–2032)?
  • What are the key findings pertaining to the market across the G11 and which country will have the largest Menkes Disease market size during the forecast period (2022–2032)?
  • At what CAGR, the Menkes Disease market is expected to grow at the G11 level during the forecast period (2022–2032)?
  • What would be the Menkes Disease market outlook across the G11 during the forecast period (2022–2032)?
  • What would be the Menkes Disease market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Menkes Disease?
  • What is the historical Menkes Disease patient pool in the G11?
  • What would be the forecasted patient pool of Menkes Disease at the G11 level?
  • What will be the growth opportunities across the G11 with respect to the patient population pertaining to Menkes Disease?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Menkes Disease during the forecast period (2022–2032)?
  • At what CAGR the population is expected to grow across the G11 during the forecast period (2022–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Menkes Disease?
  • What are the current treatment guidelines for the treatment of Menkes Disease in the US and Europe?
  • How many companies are developing therapies for the treatment of Menkes Disease?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Menkes Disease?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Menkes Disease therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Menkes Disease and their status?
  • What are the key designations that have been granted for the emerging therapies for Menkes Disease?
  • What are the G11 historical and forecasted market of Menkes Disease?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving Menkes Disease.
  • To understand the future market competition in the Menkes Disease market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Menkes Disease in the G11.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Menkes Disease market.
  • To understand the future market competition in the Menkes Disease market.

1. Key Insights

2. Report Introduction

3. Menkes Disease Market Overview at a Glance

3.1. Market Share (%) Distribution of Menkes Disease by Therapies in 2019

3.2. Market Share (%) Distribution of Menkes Disease by Therapies in 2032

4. Menkes Disease Market: Future Perspective

5. Executive Summary of Menkes Disease

6. Key Events

7. Disease Background and Overview

7.1. Introduction of Menkes Disease

7.2. Etiology of Menkes Disease

7.3. Signs and Symptoms of Menkes Disease

7.4. Pathophysiology of Menkes Disease

7.5. Differential Diagnosis

7.6. Diagnosis of Menkes Disease

7.6.1. Diagnosis Algorithm

7.6.2. Diagnosis Recommendation

7.7. Treatment and Management of Menkes Disease

7.7.1. Treatment Algorithm

7.7.2. Treatment Recommendations

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Methodology of Epidemiology

8.3. Assumptions and Rationale: G11

8.3.1. The United States

8.3.2. The Five European Countries (Germany, France, Italy, Spain, and the United Kingdom)

8.3.3. Japan

8.3.4. Australia

8.3.5. New Zealand

8.3.6. China

8.3.7. South Korea

8.4. Total Diagnosed Prevalent Cases of Menkes Disease in the G11

8.5. The United States

8.5.1. Diagnosed Prevalent Cases of Menkes Disease in the United States

8.6. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)

8.6.1. Germany

8.6.1.1. Diagnosed Prevalent Cases of Menkes Disease in Germany

8.6.2. France

8.6.2.1. Diagnosed Prevalent Cases of Menkes Disease in France

8.6.3. Italy

8.6.3.1. Diagnosed Prevalent Cases of Menkes Disease in Italy

8.6.4. Spain

8.6.4.1. Diagnosed Prevalent Cases of Menkes Disease in Spain

8.6.5. United Kingdom

8.6.5.1. Diagnosed Prevalent Cases of Menkes Disease in the United Kingdom

8.7. Japan

8.7.1. Diagnosed Prevalent Cases of Menkes Disease in Japan

8.8. Australia

8.8.1. Diagnosed Prevalent Cases of Menkes Disease in Australia

8.9. New Zealand

8.9.1. Diagnosed Prevalent Cases of Menkes Disease in New Zealand

8.10. China

8.10.1. Diagnosed Prevalent Cases of Menkes Disease in China

8.11. South Korea

8.11.1. Diagnosed Prevalent Cases of Menkes Disease in South Korea

9. Patient Journey

10. Emerging Drugs

10.1. Key Competitors

10.2. CUTX-101: Cyprium Therapeutics and Sentynl Therapeutics

10.2.1. Product Description

10.2.2. Development activities

10.2.3. Clinical Development

10.2.4. Clinical Trials Information

10.2.5. Safety and Efficacy

10.2.6. Product Profile

10.2.7. Analysts’ Views

11. Menkes Disease: G11 Analysis

11.1. Key Findings

11.2. Methodology of Menkes Disease Market

11.3. Market Outlook

11.4. Potential of Current and Emerging Therapies

11.5. Key Market Forecast Assumptions

11.6. Market Size of Menkes Disease in the G11

11.7. Market Size of Menkes Disease by Therapies in the G11

11.8. Market Size of Menkes Disease in the United States

11.8.1. Total Market Size of Menkes Disease

11.8.2. Market Size of Menkes Disease by Therapies

11.9. Market Size of Menkes Disease in the EU-5

11.9.1. Germany

11.9.1.1. Total Market size of Menkes Disease

11.9.1.2. Market Size of Menkes Disease by Therapies in Germany

11.9.2. France

11.9.2.1. Total Market size of Menkes Disease

11.9.2.2. Market Size of Menkes Disease by Therapies in France

11.9.3. Italy

11.9.3.1. Total Market size of Menkes Disease

11.9.3.2. Market Size of Menkes Disease by Therapies in Italy

11.9.4. Spain

11.9.4.1. Total Market size of Menkes Disease

11.9.4.2. Market Size of Menkes Disease by Therapies in Spain

11.9.5. United Kingdom

11.9.5.1. Total Market size of Menkes Disease

11.9.5.2. Market Size of Menkes Disease by Therapies in the United Kingdom

11.10. Market Size of Menkes Disease in Japan

11.10.1. Total Market Size of Menkes Disease

11.10.2. Market Size of Menkes Disease by Therapies

11.11. Market Size of Menkes Disease in Australia

11.11.1. Total Market Size of Menkes Disease

11.11.2. Market Size of Menkes Disease by Therapies

11.12. Market Size of Menkes Disease in New Zealand

11.12.1. Total Market Size of Menkes Disease

11.12.2. Market Size of Menkes Disease by Therapies

11.13. Market Size of Menkes Disease in China

11.13.1. Total Market Size of Menkes Disease

11.13.2. Market Size of Menkes Disease by Therapies

11.14. Market Size of Menkes Disease in South Korea

11.14.1. Total Market Size of Menkes Disease

11.14.2. Market Size of Menkes Disease by Therapies

12. Key Opinion Leaders’ Views

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. Unmet Needs

17. Reimbursement and Market Access

18. Appendix

18.1. Bibliography

18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Table

Table 1: Summary of Menkes Disease Market and Epidemiology (2019–2032)

Table 2: Key Events

Table 3: Disease background

Table 4: Diagnosed Prevalent Cases of Menkes Disease in the G11 (2019–2032)

Table 5: Diagnosed Prevalent Cases of Menkes Disease in the US (2019–2032)

Table 6: Diagnosed Prevalent Cases of Menkes Disease in EU-5 (2019–2032)

Table 7: Diagnosed Prevalent Cases of Menkes Disease in Japan (2019–2032)

Table 8: Diagnosed Prevalent Cases of Menkes Disease in Australia (2019–2032)

Table 9: Diagnosed Prevalent Cases of Menkes Disease in New Zealand (2019–2032)

Table 10: Diagnosed Prevalent Cases of Menkes Disease in China (2019–2032)

Table 11: Diagnosed Prevalent Cases of Menkes Disease in South Korea (2019–2032)

Table 12: Comparison of Emerging Drugs Under Development

Table 13: CUTX-101, Clinical Trial Description, 2022

Table 14: Key Market Forecast Assumptions for CUTX-101

Table 15: Market Size of Menkes Disease in the G11, in USD Million (2019–2032)

Table 16: Market Size of Menkes Disease by Therapies in the G11, in USD Million (2019–2032)

Table 17: Market Size of Menkes Disease in the United States, in USD Million (2019–2032)

Table 18: Market Size of Menkes Disease by Therapies in the United States, in USD Million (2019–2032)

Table 19: Market Size of Menkes Disease in the EU-5, in USD Millions (2019–2032)

Table 20: Market Size of Menkes Disease by Therapies in the EU-5, in USD Million (2019–2032)

Table 21: Market Size of Menkes Disease in Germany, in USD Millions (2019–2032)

Table 22: Market Size of Menkes Disease by Therapies in Germany, in USD Million (2019–2032)

Table 23: Market Size of Menkes Disease in France, in USD Millions (2019–2032)

Table 24: Market Size of Menkes Disease by Therapies in France, in USD Million (2019–2032)

Table 25: Market Size of Menkes Disease in Italy, in USD Million (2019–2032)

Table 26: Market Size of Menkes Disease by Therapies in Italy, in USD Million (2019–2032)

Table 27: Market Size of Menkes Disease in Spain, in USD Million (2019–2032)

Table 28: Market Size of Menkes Disease by Therapies in Spain, in USD Million (2019–2032)

Table 29: Market Size of Menkes Disease in the UK, in USD Millions (2019–2032)

Table 30: Market Size of Menkes Disease by Therapies in the UK, in USD Million (2019–2032)

Table 31: Market Size of Menkes Disease in Japan, in USD Million (2019–2032)

Table 32: Market Size of Menkes Disease by Therapies in Japan, in USD Million (2019–2032)

Table 33: Market Size of Menkes Disease in Australia, in USD Million (2019–2032)

Table 34: Market Size of Menkes Disease by Therapies in Australia, in USD Million (2019–2032)

Table 35: Market Size of Menkes Disease in New Zealand, in USD Million (2019–2032)

Table 36: Market Size of Menkes Disease by Therapies in New Zealand, in USD Million (2019–2032)

Table 37: Market Size of Menkes Disease in China, in USD Million (2019–2032)

Table 38: Market Size of Menkes Disease by Therapies in China, in USD Million (2019–2032)

Table 39: Market Size of Menkes Disease in South Korea, in USD Million (2019–2032)

Table 40: Market Size of Menkes Disease by Therapies in South Korea, in USD Million (2019–2032)

List of Figures

Figure 1: X-linked recessive inheritance pattern

Figure 2: Signs and Symptoms of Menkes Disease

Figure 3: MRI Brain (T2W axial view)

Figure 4: Early diagnosis and treatment of Menkes Disease

Figure 5: Treatment algorithm as per NHS

Figure 6: Diagnosed Prevalent Cases of Menkes Disease in the G11 (2019–2032)

Figure 7: Diagnosed Prevalent Cases of Menkes Disease in the US (2019–2032)

Figure 8: Diagnosed Prevalent Cases of Menkes Disease in EU-5 (2019–2032)

Figure 9: Diagnosed Prevalent Cases of Menkes Disease in Japan (2019–2032)

Figure 10: Diagnosed Prevalent Cases of Menkes Disease in Australia (2019–2032)

Figure 11: Diagnosed Prevalent Cases of Menkes Disease in New Zealand (2019–2032)

Figure 12: Diagnosed Prevalent Cases of Menkes Disease in China (2019–2032)

Figure 13: Diagnosed Prevalent Cases of Menkes Disease in South Korea (2019–2032)

Figure 14: Patient Journey

Figure 15: Market Size of Menkes Disease in the G11, in USD Million (2019–2032)

Figure 16: Market Size of Menkes Disease by Therapies in the G11, in USD Million (2019–2032)

Figure 17: Market Size of Menkes Disease in the United States, in USD Million (2019–2032)

Figure 18: Market Size of Menkes Disease by Therapies in the United States, in USD Million (2019–2032)

Figure 19: Market Size of Menkes Disease in the EU-5, in USD Millions (2019–2032)

Figure 20: Market Size of Menkes Disease by Therapies in the EU-5, in USD Million (2019–2032)

Figure 21: Market Size of Menkes Disease in Germany, in USD Millions (2019–2032)

Figure 22: Market Size of Menkes Disease by Therapies in Germany, in USD Million (2019–2032)

Figure 23: Market Size of Menkes Disease in France, in USD Millions (2019–2032)

Figure 24: Market Size of Menkes Disease by Therapies in France, in USD Million (2019–2032)

Figure 25: Market Size of Menkes Disease in Italy, in USD Million (2019–2032)

Figure 26: Market Size of Menkes Disease by Therapies in Italy, in USD Million (2019–2032)

Figure 27: Market Size of Menkes Disease in Spain, in USD Million (2019–2032)

Figure 28: Market Size of Menkes Disease by Therapies in Spain, in USD Million (2019–2032)

Figure 29: Market Size of Menkes Disease in the UK, in USD Millions (2019–2032)

Figure 30: Market Size of Menkes Disease by Therapies in the UK, in USD Million (2019–2032)

Figure 31: Market Size of Menkes Disease in Japan, in USD Million (2019–2032)

Figure 32: Market Size of Menkes Disease by Therapies in Japan, in USD Million (2019–2032)

Figure 33: Market Size of Menkes Disease in Australia, in USD Million (2019–2032)

Figure 34: Market Size of Menkes Disease by Therapies in Australia, in USD Million (2019–2032)

Figure 35: Market Size of Menkes Disease in New Zealand, in USD Million (2019–2032)

Figure 36: Market Size of Menkes Disease by Therapies in New Zealand, in USD Million (2019–2032)

Figure 37: Market Size of Menkes Disease in China, in USD Million (2019–2032)

Figure 38: Market Size of Menkes Disease by Therapies in China, in USD Million (2019–2032)

Figure 39: Market Size of Menkes Disease in South Korea, in USD Million (2019–2032)

Figure 40: Market Size of Menkes Disease by Therapies in South Korea, in USD Million (2019–2032)

Figure 41: Market Drivers

Figure 42: Market Barriers

Figure 43: SWOT Analysis

Figure 44: Unmet Needs

Cyprium Therapeutics and Sentynl Therapeutics

 

Forward to Friend

Need A Quote